4D Molecular Therapeutics (FDMT) Capital Expenditures (QoQ) (2020 - 2025)
4D Molecular Therapeutics (FDMT) Capital Expenditures (QoQ) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,848.35% |
| Sep 30, 2025 | -116.34% |
| Jun 30, 2025 | 297.86% |
| Mar 31, 2025 | -85.25% |
| Dec 31, 2024 | -46.63% |
| Sep 30, 2024 | 409.46% |
| Jun 30, 2024 | -50.85% |
| Mar 31, 2024 | 135.71% |
| Dec 31, 2023 | -204.08% |
| Sep 30, 2023 | 372.86% |
| Jun 30, 2023 | -169.17% |
| Mar 31, 2023 | 330.00% |
| Dec 31, 2022 | 94.52% |
| Sep 30, 2022 | -488.58% |
| Jun 30, 2022 | -67.78% |
| Mar 31, 2022 | 25.84% |
| Dec 31, 2021 | 38.97% |
| Sep 30, 2021 | 1,715.35% |
| Jun 30, 2021 | 39.31% |
| Sep 30, 2020 | -230.69% |